H.C. Wainwright analyst Emily Bodnar assumed coverage of TG Therapeutics (TGTX) with a Buy rating and $60 price target The firm expects Briumvi’s market penetration to grow significantly in the next few years. The company is building a franchise in the treatment of multiple sclerosis, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG announces updated data presentations from ULTIMATE I, II Phase 3 trials
- TG Therapeutics price target raised to $55 from $53 at B. Riley
- TG Therapeutics says enrollment commenced for Phase 3 trial of BRIUMVI
- Alphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz
- TG Therapeutics completes share repurchase program, authorize new $100M program